Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2023 Sep 8;17(1):383.
doi: 10.1186/s13256-023-04086-7.

Sinopharm (HB02)-associated vaccine-induced immune thrombotic thrombocytopenia: a case report

Mohammad Sistanizad  1   2 , Tahereh Sabaghian  3 , Hossein Amini  1 , Fahimeh Hadavand  4   5 , Mahmood Nabavi  4   5 , Mehran Kouchek  6 , Mir Mohammad Miri  6 , Sara Salarian  6 , Seyedpouzhia Shojaei  6 , Omid Moradi  7
Affiliations
Case Reports

Sinopharm (HB02)-associated vaccine-induced immune thrombotic thrombocytopenia: a case report

Mohammad Sistanizad et al. J Med Case Rep. .

Abstract

Background: Vaccine-induced thrombotic thrombocytopenia is associated with the coronavirus disease 2019 vaccines. It has been reported by vector-based vaccines. To the best of our knowledge, there is no report about vaccine-induced thrombotic thrombocytopenia in whole-virus vaccines. We are presenting the first case of vaccine-induced thrombotic thrombocytopenia with this type of vaccine.

Case presentation: An 18-year-old male Caucasian patient with complaints of severe abdominal, low back, and lower extremity pain presented to the medical center. He received the first dose of the Sinopharm (HB02) vaccine against coronavirus disease 2019 10 days before hospital attendance. In the laboratory examination, decreased platelet count and increased D-dimer were observed. During hospital admission, the diagnosis of pulmonary embolism was reached. He received vaccine-induced thrombotic thrombocytopenia therapy consisting of intravenous immune globulin and direct oral anticoagulant. Platelet count increased and he was discharged after 1 month.

Conclusion: This case highlights the possibility of vaccine-induced thrombotic thrombocytopenia occurrence by whole-virus coronavirus disease 2019 vaccines. Compared with vector-based vaccines, this phenomenon is rare for whole-virus vaccines. More studies on this type of vaccine regarding thrombotic thrombocytopenia should be considered.

Keywords: COVID-19; Case report; Thrombosis; Vaccine; Whole-virus vaccine.

PubMed Disclaimer

Conflict of interest statement

The authors declared none.

Figures

Fig. 1
Fig. 1
Patient timeline
See this image and copyright information in PMC

References

    1. Lipsitch M, Dean NE. Understanding COVID-19 vaccine efficacy. Science. 2020;370(6518):763–765. doi: 10.1126/science.abe5938. - DOI - PubMed
    1. Laine C, Cotton D, Moyer DV. COVID-19 vaccine: what physicians need to know. Ann Intern Med. 2020;173(10):830. doi: 10.7326/M20-6841. - DOI - PMC - PubMed
    1. Xia S, Duan K, Zhang Y, et al. Effect of an inactivated vaccine against SARS-CoV-2 on safety and immunogenicity outcomes: interim analysis of 2 randomized clinical trials. JAMA. 2020;324(10):951–960. doi: 10.1001/jama.2020.15543. - DOI - PMC - PubMed
    1. Xia S, Zhang Y, Wang Y, et al. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial. Lancet Infect Dis. 2021;21(1):39–51. doi: 10.1016/S1473-3099(20)30831-8. - DOI - PMC - PubMed
    1. Schultz NH, Sørvoll IH, Michelsen AE, et al. Thrombosis and thrombocytopenia after ChAdOx1 nCoV-19 vaccination. N Engl J Med. 2021;384(22):2124–2130. doi: 10.1056/NEJMoa2104882. - DOI - PMC - PubMed

Publication types